Listing 13.23 Female Genital Tract Cancer in 2026
Female genital tract cancers cover a wide anatomic and biological range. The American Cancer Society projects for 2026: uterine corpus cancer 68,510 new US cases + 13,860 deaths (rising incidence), ovarian cancer 20,180 new cases + 12,730 deaths (declining incidence but worst prognosis), cervical cancer 12,890 new cases + 3,860 deaths (declining thanks to HPV vaccination and screening), vulvar cancer 6,720 cases + 1,600 deaths, vaginal cancer 5,660 cases + 1,540 deaths, fallopian tube (grouped with ovarian).
SSA Listing 13.23 covers all these under one section with three paragraphs plus a special provision for small cell ovarian carcinoma. This walkthrough covers histologic subtypes, molecular testing including BRCA1/2 and MMR, PARP inhibitor maintenance, checkpoint inhibitor and antibody-drug conjugate revolution across all subsites, and surgical residuals including lymphedema.
See If You Qualify
The listing text
Paragraph A: Small cell carcinoma of the ovary, uterus, cervix, or vagina; or vulvar cancer T4 with regional or distant nodes; or cervical squamous cell with regional or distant nodes
Small cell (extrapulmonary neuroendocrine) carcinoma of any female genital site automatically qualifies. This aggressive high-grade neuroendocrine tumor behaves like small cell lung cancer with rapid progression and high metastatic potential.
Paragraph B: Recurrent disease
Recurrent cancer of any female genital site after prior treatment qualifies. Ovarian cancer recurs in about 70% of patients with advanced disease. Endometrial cancer recurs in about 15% of surgically treated patients (higher for advanced stages). Cervical cancer recurrent rate 20-40% depending on stage.
Paragraph C: Metastases beyond regional lymph nodes
Regional nodes vary by primary site. Metastases beyond regional nodes to distant sites qualify. Common patterns:
- Ovarian: peritoneal carcinomatosis, omentum, liver, pleural effusions, distant nodes
- Uterine: lung, liver, distant nodes, bone (with serous histology often mimicking ovarian)
- Cervical: para-aortic nodes (technically not regional beyond a point), lung, liver, bone
- Vulvar/vaginal: inguinal nodes are regional, pelvic/distant sites when beyond
Ovarian cancer
Epithelial ovarian cancer (95%)
High-grade serous carcinoma (HGSC) is dominant subtype (70-80% of epithelial). Recognized as often arising from fallopian tube fimbria rather than ovary itself, hence combined ovarian/tubal/primary peritoneal terminology. Other subtypes: endometrioid (10%), clear cell (10%, chemoresistant), mucinous (3%), low-grade serous (5%). Presents typically at stage III (peritoneal spread) or IV (distant).
Germ cell tumors (5%)
Dysgerminoma, immature teratoma, endodermal sinus tumor, embryonal carcinoma, choriocarcinoma. Affects younger women. Chemosensitive (BEP regimen highly curative).
Sex cord-stromal tumors
Granulosa cell tumor (produces inhibin), Sertoli-Leydig cell tumor. Generally indolent but can recur late.
Small cell carcinoma of ovary (hypercalcemic type)
Rare, aggressive. Automatically meets 13.23A.
Ovarian cancer treatment
- Primary cytoreductive surgery + platinum/taxane chemotherapy
- Neoadjuvant chemo + interval debulking for extensive disease
- Bevacizumab (GOG-0218): improves PFS when added to chemo and continued as maintenance
- PARP inhibitor maintenance:
- Olaparib for germline BRCA1/2 (SOLO-1 first-line)
- Olaparib + bevacizumab for HRD-positive (PAOLA-1 first-line)
- Niraparib for all comers (PRIMA first-line)
- Mirvetuximab soravtansine (FR-alpha ADC with DM4 payload) for FR-alpha high, platinum-resistant ovarian per MIRASOL. Toxicities: ocular disorders (blurred vision, keratopathy), peripheral neuropathy, pneumonitis.
Uterine (endometrial) cancer
Molecular classification (TCGA/ProMisE)
- POLE ultramutated (~7%) - excellent prognosis
- MMR-deficient (~30%) - immunotherapy responsive
- p53-abnormal (~15%) - serous-like, worst prognosis
- No specific molecular profile (~50%) - intermediate
Histologic subtypes
- Endometrioid (80%) - most common, generally lower grade
- Serous (10%) - aggressive, resembles ovarian HGSC, p53-mutated
- Clear cell (5%) - aggressive
- Carcinosarcoma (mixed epithelial + sarcomatoid) - aggressive
- Uterine sarcomas: leiomyosarcoma, endometrial stromal sarcoma, adenosarcoma
Endometrial cancer treatment
- Total hysterectomy + bilateral salpingo-oophorectomy + sentinel node biopsy or pelvic/para-aortic lymphadenectomy
- Adjuvant radiation (external beam or vaginal brachytherapy) for stage I/II with high-risk features
- Chemotherapy (carbo/paclitaxel) for advanced or high-risk histology
- Dostarlimab + carbo/paclitaxel for dMMR advanced/recurrent endometrial (RUBY) - first-line standard 2023
- Pembrolizumab + lenvatinib for pMMR advanced/recurrent (KEYNOTE-775)
- HER2-targeted therapy (T-DXd) for HER2-positive serous
Cervical cancer
Histology
- Squamous cell carcinoma (70%) - HPV-associated
- Adenocarcinoma (25%) - HPV-associated
- Adenosquamous, small cell, other (5%)
Cervical cancer treatment
- Early stage (IA, IB1): cone biopsy, simple or radical hysterectomy, or fertility-sparing options
- Locally advanced (IB3-IVA): concurrent chemoradiation with weekly cisplatin + external beam + brachytherapy
- Pembrolizumab + chemo +/- bevacizumab for advanced/recurrent (KEYNOTE-826) - first-line standard
- Cemiplimab for recurrent (EMPOWER-Cervical)
- Tisotumab vedotin (tissue factor ADC with MMAE payload) for recurrent per innovaTV 204. Toxicities: ocular events (mandatory eye care protocol), CIPN, hemorrhage.
Vulvar and vaginal cancer
Squamous cell dominant (both HPV-associated and HPV-independent). Treatment: wide local excision + inguinofemoral lymphadenectomy for vulvar; chemoradiation for vaginal. Advanced disease may require pelvic exenteration.
Biomarker testing (2026 standard)
- BRCA1/2 germline testing for all ovarian, fallopian, primary peritoneal cancer
- Somatic BRCA testing (in tumor) if germline negative
- HRD (homologous recombination deficiency) testing for ovarian - drives niraparib and olaparib + bev decisions
- MMR/MSI for all endometrial and colorectal-associated GU cancers
- PD-L1 CPS for cervical (drives pembrolizumab), some uterine
- HER2 for endometrial serous
- FR-alpha for ovarian (drives mirvetuximab)
- Comprehensive genomic profiling for advanced/recurrent disease
The Compassionate Allowance overlay
Ovarian cancer with distant metastases, stage III/IV endometrial cancer, and stage IV cervical cancer are on the CAL list. Small cell ovarian carcinoma also on CAL. These trigger 14-30 day expedited processing.
Surgical residuals for the CDR
Radical hysterectomy + pelvic lymphadenectomy
Standard for cervical cancer stage IB/IIA and some early endometrial. Residuals: pelvic lymphedema (up to 30%), sexual dysfunction (nerve injury, vaginal shortening), bladder dysfunction (up to 50% urinary retention or incontinence), bowel dysfunction, chronic pain.
Inguinofemoral lymphadenectomy
For vulvar cancer. Residuals: leg lymphedema (up to 50%), wound breakdown, cellulitis recurrence, chronic pain.
Total pelvic exenteration
Ultra-radical surgery for centrally recurrent cervical cancer or advanced vulvar/vaginal cancer. Removal of bladder, uterus/cervix/vagina, rectum, and pelvic reproductive organs. Requires urinary diversion (ileal conduit) + colostomy or coloanal anastomosis + neovagina reconstruction. Devastating quality of life impact. 5-year survival about 40-50% in selected patients.
Chemotherapy-induced peripheral neuropathy from taxanes/platinums
Universal in patients receiving multiple lines of carbo/paclitaxel. Often persistent or permanent.
Radiation-induced pelvic damage
Chronic radiation cystitis, proctitis, enteritis. Vaginal stenosis. Chronic pelvic pain. Insufficiency fractures of pelvic bones.
Worked case examples
Case 1: Sarah, 55, California, BRCA1 germline, stage IIIC high-grade serous ovarian cancer on olaparib maintenance
Sarah presented with abdominal distension and early satiety January 2026. CT showed omental caking, ascites, pelvic mass. CA-125 3,200. Diagnostic paracentesis: malignant cells. Underwent primary cytoreductive surgery: total hysterectomy + BSO + omentectomy + peritonectomy + colon resection with primary anastomosis. Optimal cytoreduction (no residual disease). Pathology: high-grade serous ovarian carcinoma stage IIIC. Germline BRCA1 positive.
SSDI application filed February 2026. CAL for advanced ovarian cancer. Approved 11 days at California DDS. Adjuvant carbo/paclitaxel + bevacizumab, then olaparib maintenance per SOLO-1. Ongoing at 18 months. Chronic taxane-induced neuropathy in hands and feet. Anemia from olaparib requiring dose adjustment.
Case 2: Angela, 66, Illinois, MMR-deficient advanced endometrial cancer on dostarlimab + carbo/paclitaxel
Angela presented with post-menopausal bleeding March 2026. Endometrial biopsy: FIGO grade 3 endometrioid adenocarcinoma, dMMR by IHC (loss of MLH1 and PMS2). Underwent total hysterectomy + BSO + sentinel node biopsy: stage IIIC1 with 2 positive pelvic nodes. Adjuvant dostarlimab + carbo/paclitaxel per RUBY, then dostarlimab maintenance.
SSDI application filed April 2026. Listing 13.23C met (regional nodal). CAL for stage III endometrial. Approved 12 days at Illinois DDS. Complete response. Ongoing dostarlimab maintenance. Grade 2 immune hypothyroidism (permanent, levothyroxine).
Case 3: Maria, 47, Texas, recurrent cervical squamous cell cancer on tisotumab vedotin
Maria initially treated for stage IIB cervical squamous cell carcinoma 2023 with concurrent chemoradiation. Surveillance imaging January 2026 showed pelvic sidewall recurrence and para-aortic nodes. Biopsy confirmed. PD-L1 CPS 3. First-line pembrolizumab + chemo per KEYNOTE-826, then progression at 8 months. Second-line tisotumab vedotin.
SSDI application filed February 2026. Listing 13.23B (recurrent) and 13.23C (para-aortic nodes) met. CAL for stage IV cervical. Approved 9 days at Texas DDS. Partial response on tisotumab. Chronic ocular events requiring pre-medication eye care protocol. Chronic peripheral neuropathy.
What to file with your application
- Pathology report with histologic type, grade, FIGO staging
- Germline BRCA1/2 for ovarian/fallopian/primary peritoneal
- MMR/MSI testing for endometrial
- HRD testing for ovarian if considering PARP-eligible maintenance
- PD-L1 CPS for cervical
- FR-alpha for ovarian (if considering mirvetuximab)
- Cross-sectional imaging (CT chest/abdomen/pelvis, MRI pelvis for cervical/uterine)
- PET-CT for staging
- CA-125 for ovarian
- Operative note + final surgical pathology
- Radiation therapy summary if applicable
- Oncology consultation notes with FIGO stage and treatment plan
Related reading
Full section walkthrough: Section 13.00 cancer basics. Other cancer listings: 13.10 breast, 13.21 kidney/bladder, 13.24 prostate.
Frequently asked questions
Does every gynecologic cancer qualify for SSDI?
Very early disease (FIGO IA endometrial with grade 1 histology, cervical carcinoma in situ, borderline ovarian tumors) treated by simple surgery with negative margins may not meet 13.23. Any stage IB+ disease, higher grade, nodal involvement, recurrent disease, or metastatic disease meets. Small cell ovarian carcinoma always meets 13.23A.
What are the CAL triggers?
Ovarian cancer with distant metastases, stage III/IV endometrial cancer, stage IV cervical cancer, and small cell ovarian carcinoma are on the CAL list. These trigger 14-30 day expedited processing.
Do I need BRCA testing for ovarian cancer?
Yes. Germline BRCA1/2 testing is standard for all epithelial ovarian, fallopian, or primary peritoneal cancer per NCCN. About 20% carry a germline mutation. Drives PARP inhibitor maintenance decisions.
What about HRD testing?
Homologous recombination deficiency (HRD) testing expands beyond BRCA to identify tumors likely to respond to PARP inhibitors. Positive result opens olaparib + bevacizumab or niraparib maintenance options even without BRCA mutation.
Can pelvic lymphedema qualify at CDR?
Yes. Chronic pelvic or leg lymphedema after radical hysterectomy + pelvic lymphadenectomy, or inguinofemoral lymphadenectomy for vulvar cancer, can support continued disability under 13.00P treatment complications framework.
What is pelvic exenteration?
Ultra-radical surgery for centrally recurrent cervical cancer or advanced vulvar/vaginal cancer. Removes bladder, uterus/cervix/vagina, rectum, and reproductive organs. Requires urinary diversion + colostomy + neovagina. Devastating functional impact.
Does HPV vaccination status affect SSDI?
No. Vaccination status is irrelevant to disability determination. SSDI is based on the cancer diagnosis, staging, and treatment residuals, not on how the cancer could have been prevented.
Next steps
If you were diagnosed with gynecologic cancer, file for SSDI immediately after pathology confirmation. Small cell ovarian, stage IV disease across subsites, and advanced endometrial or cervical cancer trigger CAL fast-track.